Review and forecast21 Oct 2021 11:22
Meandering thoughts as I plan for 2022 written at the point when the latest variant for Covid 19 dubbed Delta-plus is of concern in the UK. This is my review of my portfolio during 2021 - some projections were correct and many have not occured. Some were totally wrong. I had expected uplift this year of 14.94% and am on target to achieve 16.15%.
My predictions were based on emerging from a pandemic and re-adjust to more normal times. I predicted rollout of vaccine from June (pessimistic) and uptake of 90% for those aged 16+ by end of August through the temporary Nightingale hospitals. Mis-information and poor take up has scuppered efforts. I predicted the furlough relief scheme mwould not have been extended and cause a substantial rise in unemployment and many company insolvencies. Zombie companies have all the hallmarks of struggling through to the New year and then curling up their toes. This should benefit my shares in pawnbrokers and insolvency accountants.
I was hopelessly wrong with travel in expectation that through vaccine program domestic travel to Europe would benefit with a proper vaccine passport and rapid screening test at point of arrival from say TTG Electronics. Again, wrong for 2021, but expected to be much stronger in 2022. I'll continue to dribble cash into airlines and cruise industry. I've also strengthened my holdings in utilities in emerging markets (UEM) and bought shares in investment trusts concerned with India, the Pacific Rim and broad exposure to Asia. These include Asian total Return, IGC, AAIF, PHI and TEM. China is going to continue to be a powerhouse for another decade or more so made sense to hang onto holding in Jupiter China bought 9 years ago.
A big surprise was that there has not been resumption of elective surgery to clear the huge backlog would entail to the benefit of holdings in cleanliness. I have doubled up on my holding in Tristel and have maintained my interest in DRDR, Zoetis, illumina, Roche, Thermo Fisher, IShares IV Healthcare, Abcam and a few others. Elekta has been a disapointment. Of course, not all gloom and doom. IT remains in strength and well respresented for me with ATT (actually a 7 bagger), NVDA, ADBE and Polar Capital Global Technology. Consumer discretionary is starting to build (Aubrey, DS Smith etc) and in turn helps companies in the Fintech area such as Adyen, Mastercard, Boku, IShares V Financial Sector, Augmentum and CME. Staples stay in fashion of course - so that takes care of holdings in Nestle, Fevertree and oil runs the world so I have a few shares still with RDSB.
My shares in housebuilders have all been sold in favour ofinvestment trusts targetting smaller companies both UK and EU based - MINI, MTE and MTU along with various "Special Situations" ITs focussing on USA, Pacific Rim and South America. Inflation is of concern so I have T44 gilts........